New Zealand markets close in 3 hours 47 minutes

Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I (INDP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.3200-0.1700 (-6.83%)
At close: 04:00PM EDT
2.4300 +0.11 (+4.74%)
After hours: 07:50PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.4900
Open2.4600
Bid1.7300 x 200
Ask2.9800 x 200
Day's range2.3200 - 2.5350
52-week range1.5600 - 4.0800
Volume33,551
Avg. volume30,127
Market cap21.262M
Beta (5Y monthly)1.23
PE ratio (TTM)N/A
EPS (TTM)-1.7700
Earnings date12 Aug 2024 - 16 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit

    - Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its founder and Chief Scientific Officer, Michael Newman, Ph.D., will present additional data on the Comp

  • GlobeNewswire

    Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

    NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on the Company’s lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024. Dr. Waltzman will present preliminary results from the Company’s ongoin

  • GlobeNewswire

    Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

    Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced updated data from its ongoing Phase 1 c